258 related articles for article (PubMed ID: 28099598)
1. Dermatoscopy-guided therapy of pigmented basal cell carcinoma with imiquimod.
Husein-ElAhmed H; Fernandez-Pugnaire MA
An Bras Dermatol; 2016; 91(6):764-769. PubMed ID: 28099598
[TBL] [Abstract][Full Text] [Related]
2. [Dermoscopic signs as predictors of non-response to imiquimod treatment in superficial basal cell carcinoma].
Aróstegui Aguilar J; Hervella Garcés M; Yanguas Bayona JI; Azcona Rodríguez M; Martínez de Espronceda Ezquerro I; Sarriugarte Aldecoa-Otalora J
An Sist Sanit Navar; 2019 Dec; 42(3):303-307. PubMed ID: 31859267
[TBL] [Abstract][Full Text] [Related]
3. The use of dermatoscopy to monitor therapeutic response of Bowen disease: a dermatoscopic pathological study.
Mun JH; Park JM; Song M; Jwa SW; Kim HS; Ko HC; Kim BS; Kim MB
Br J Dermatol; 2012 Dec; 167(6):1382-5. PubMed ID: 22759263
[TBL] [Abstract][Full Text] [Related]
4. Role of In Vivo Reflectance Confocal Microscopy in the Analysis of Melanocytic Lesions.
Serban ED; Farnetani F; Pellacani G; Constantin MM
Acta Dermatovenerol Croat; 2018 Apr; 26(1):64-67. PubMed ID: 29782304
[TBL] [Abstract][Full Text] [Related]
5. Lentigo maligna treated with topical imiquimod: dermatoscopy usefulness in clinical monitoring.
Costa MC; Abraham LS; Barcaui C
An Bras Dermatol; 2011; 86(4):792-4. PubMed ID: 21987152
[TBL] [Abstract][Full Text] [Related]
6. Dermatoscopy of basal cell carcinoma: morphologic variability of global and local features and accuracy of diagnosis.
Altamura D; Menzies SW; Argenziano G; Zalaudek I; Soyer HP; Sera F; Avramidis M; DeAmbrosis K; Fargnoli MC; Peris K
J Am Acad Dermatol; 2010 Jan; 62(1):67-75. PubMed ID: 19828209
[TBL] [Abstract][Full Text] [Related]
7. Letter: Changes in dermoscopic features in superficial basal cell carcinomas treated with imiquimod.
Micantonio T; Fargnoli MC; Piccolo D; Peris K
Dermatol Surg; 2007 Nov; 33(11):1403-5. PubMed ID: 17958603
[No Abstract] [Full Text] [Related]
8. Dermoscopic features of basal cell carcinoma and its subtypes: A systematic review.
Reiter O; Mimouni I; Dusza S; Halpern AC; Leshem YA; Marghoob AA
J Am Acad Dermatol; 2021 Sep; 85(3):653-664. PubMed ID: 31706938
[TBL] [Abstract][Full Text] [Related]
9. Peculiar clinical and dermoscopic remission pattern following imiquimod therapy of basal cell carcinoma in seborrhoeic areas of the face.
Diluvio L; Campione E; Paternò EJ; Orlandi A; Terrinoni A; Chimenti S
J Dermatolog Treat; 2009; 20(2):124-9. PubMed ID: 18991155
[TBL] [Abstract][Full Text] [Related]
10. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from a randomized vehicle-controlled phase III study in Europe.
Schulze HJ; Cribier B; Requena L; Reifenberger J; Ferrándiz C; Garcia Diez A; Tebbs V; McRae S
Br J Dermatol; 2005 May; 152(5):939-47. PubMed ID: 15888150
[TBL] [Abstract][Full Text] [Related]
11. Dermoscopy uncovers clinically undetectable pigmentation in basal cell carcinoma.
Lallas A; Argenziano G; Kyrgidis A; Apalla Z; Moscarella E; Longo C; Ferrara G; Piana S; Benati E; Zendri E; Sotiriou E; Zalaudek I
Br J Dermatol; 2014 Jan; 170(1):192-5. PubMed ID: 24117444
[TBL] [Abstract][Full Text] [Related]
12. The relation between dermoscopy and histopathology of basal cell carcinoma.
Emiroglu N; Cengiz FP; Kemeriz F
An Bras Dermatol; 2015; 90(3):351-6. PubMed ID: 26131865
[TBL] [Abstract][Full Text] [Related]
13. Dermoscopic Ulceration is a Predictor of Basal Cell Carcinoma Response to Imiquimod: A Retrospective Study.
Urech M; Kyrgidis A; Argenziano G; Reggiani C; Moscarella E; Longo C; Alfano R; Zalaudek I; Lallas A
Acta Derm Venereol; 2017 Jan; 97(1):117-119. PubMed ID: 27230691
[No Abstract] [Full Text] [Related]
14. Imiquimod: in superficial basal cell carcinoma.
Oldfield V; Keating GM; Perry CM
Am J Clin Dermatol; 2005; 6(3):195-200; discussion 201-2. PubMed ID: 15943496
[TBL] [Abstract][Full Text] [Related]
15. Dermoscopic features of small size pigmented basal cell carcinomas.
Takahashi A; Hara H; Aikawa M; Ochiai T
J Dermatol; 2016 May; 43(5):543-6. PubMed ID: 26458728
[TBL] [Abstract][Full Text] [Related]
16. Correlation between the dermatoscopic and histopathological features of pigmented basal cell carcinoma.
Tabanlıoğlu Onan D; Sahin S; Gököz O; Erkin G; Cakır B; Elçin G; Kayıkçıoğlu A
J Eur Acad Dermatol Venereol; 2010 Nov; 24(11):1317-25. PubMed ID: 20337825
[TBL] [Abstract][Full Text] [Related]
17. Confirmation of histological clearance of superficial basal cell carcinoma with multiple serial sectioning and Mohs' micrographic surgery following treatment with imiquimod 5% cream.
Ezughah FI; Affleck AG; Evans A; Ibbotson SH; Fleming CJ
J Dermatolog Treat; 2008; 19(3):156-8. PubMed ID: 18569271
[TBL] [Abstract][Full Text] [Related]
18. Pilot study using topical imiquimod 5% cream in the treatment of nodular basal cell carcinoma after initial treatment with curettage.
Neville JA; Williford PM; Jorizzo JL
J Drugs Dermatol; 2007 Sep; 6(9):910-4. PubMed ID: 17941362
[TBL] [Abstract][Full Text] [Related]
19. Vitiligo-like depigmentation induced by imiquimod treatment of superficial basal cell carcinoma.
Sriprakash K; Godbolt A
Australas J Dermatol; 2009 Aug; 50(3):211-3. PubMed ID: 19659986
[TBL] [Abstract][Full Text] [Related]
20. Excellent response of basal cell carcinomas and pigmentary changes in xeroderma pigmentosum to imiquimod 5% cream.
Nagore E; Sevila A; Sanmartin O; Botella-Estrada R; Requena C; Serra-Guillen C; Sanchez-Pedreño P; Guillen C
Br J Dermatol; 2003 Oct; 149(4):858-61. PubMed ID: 14616381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
